<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865277</url>
  </required_header>
  <id_info>
    <org_study_id>STR-INDIRA-MISO-2014</org_study_id>
    <nct_id>NCT03865277</nct_id>
  </id_info>
  <brief_title>Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging</brief_title>
  <acronym>INDIRA-MISO</acronym>
  <official_title>Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging: Multi-center, Randomized Phase-II-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial evaluates the value of radiation dose escalation based on Hypoxia detection by&#xD;
      18F_misonidazole Positron Emission Tomography (18F-MISO-PET) for primary radiochemotherapy of&#xD;
      head and neck squamous cell carcinoma. Patients negative for human papillomavirus (HPV) and&#xD;
      with hypoxic tumours after 2 weeks of radiochemotherapy are randomized to completion of&#xD;
      standard radiochemotherapy or radiochemotherapy with escalated radiation dose. An additional&#xD;
      interventional arm includes a carbon ion boost. HPV positive tumours can be included in a&#xD;
      control arm. Primary endpoint is local tumour control 2 years after radiochemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous preclinical data and a prospective validated patient cohort have shown that patients&#xD;
      with head and neck squamous cell carcinoma, whose tumours are hypoxic after 2 weeks of&#xD;
      primary radiochmeotherapy, have a significantly lower chance of locoregional tumour control.&#xD;
      The multi-center trial evaluates the value of radiation dose escalation based on hypoxia&#xD;
      detection by 18F_misonidazole Positron Emission Tomography (18F-MISO-PET) for primary&#xD;
      radiochemotherapy of head and neck squamous cell carcinoma. Patients negative for human&#xD;
      papillomavirus (HPV) and with hypoxic tumours after 2 weeks of radiochemotherapy are&#xD;
      randomized to completion of standard radiochemotherapy (70 Gy) or radiochemotherapy with&#xD;
      escalated radiation dose (77 Gy). An additional interventional arm includes a carbon ion&#xD;
      boost to 77 Gy. HPV positive tumours can be included in a control arm. Primary endpoint is&#xD;
      local tumour control 2 years after radiochemotherapy. Secondary endpoints include acute and&#xD;
      late toxicity (CTCAE 5.0), regional tumor control, overall survival, disease free survival,&#xD;
      distant metastases, kinetics analysis of dynamic FMISO-PET scans, Quality of life (QoL). The&#xD;
      hypothesis is that local tumour control 2 years after radiochemotherapy is higher in the dose&#xD;
      escalated compared to the control arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local tumour control</measure>
    <time_frame>Local tumor control 2 years after end of treatment</time_frame>
    <description>Local tumour control (MRI, CT, PET or clinical evaluation) in the randomized dose-escalated arm compared to the randomized non dose escalated arm (arms 1 and 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>30 days to 2 years after radiochemotherapy</time_frame>
    <description>late toxicity based on CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>2 years after radiochemotherapy</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life EORTC QLQ-C30/HN-35</measure>
    <time_frame>regularly up to 2 years after radiochemotherapy</time_frame>
    <description>EORTC-QLQ (C30 and HN-35) Sheets (General for tumour diseases and specific for head and neck cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>during treatment and up to 30 days after radiochemotherapy</time_frame>
    <description>acute toxicity based on CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>standard radiochemotherapy, hypoxic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose-escalated radiochemotherapy, hypoxic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escalated radiochemoth., carbon boost, hypoxic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard radiochemotherapy, oxic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard radiochemotherapy (70 Gy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose-escalated radiochemotherapy</intervention_name>
    <description>Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).&#xD;
Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if &quot;hypoxic&quot; and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases &gt; 2 cm.&#xD;
Radiotherapy is always applied with 5 fractions per week.</description>
    <arm_group_label>dose-escalated radiochemotherapy, hypoxic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose-escalated radiochemotherapy with carbon ion boost</intervention_name>
    <description>Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.&#xD;
Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if &quot;hypoxic&quot; and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases &gt; 2 cm using a carbon ion boost.&#xD;
Radiotherapy is always applied with 5 fractions per week.</description>
    <arm_group_label>escalated radiochemoth., carbon boost, hypoxic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard radiochemotherapy</intervention_name>
    <description>Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).&#xD;
Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.&#xD;
Radiotherapy is always applied with 5 fractions per week.</description>
    <arm_group_label>standard radiochemotherapy (70 Gy)</arm_group_label>
    <arm_group_label>standard radiochemotherapy, hypoxic</arm_group_label>
    <arm_group_label>standard radiochemotherapy, oxic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: older than 18 years&#xD;
&#xD;
          -  WHO (ECOG) performance status 0-2&#xD;
&#xD;
          -  Histological proven HNSCC&#xD;
&#xD;
          -  HPV negative tumors or HPV positive tumors&#xD;
&#xD;
          -  Stage III, IVA or IVB HNSCC according to UICC and AJCC guidelines&#xD;
&#xD;
          -  Tumor classified as irresectable or patient inoperable or patient refused surgery&#xD;
&#xD;
          -  Tumor extension and localization suitable for radiochemotherapy with curative intent&#xD;
&#xD;
          -  Simultaneous standard chemotherapy with cisplatin applicable (no contra-indications)&#xD;
&#xD;
          -  Dental examination and -treatment before start of therapy&#xD;
&#xD;
          -  For women with childbearing potential and men in reproductive ages adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the patients to take part in the trial&#xD;
&#xD;
          -  Presence of distant metastases (UICC stage IVC)&#xD;
&#xD;
          -  Previous radiotherapy in the head and neck region&#xD;
&#xD;
          -  Second malignancy that is likely to require treatment during the trial intervention or&#xD;
             follow-up period or that, in the opinion of the physician, has a considerable risk of&#xD;
             recurrence or metastases within the follow-up period&#xD;
&#xD;
          -  Serious disease or medical condition with life expectancy of less than one year&#xD;
&#xD;
          -  Participation in competing interventional trial on cancer treatment&#xD;
&#xD;
          -  Patients who are not suitable for radiochemotherapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients not able to understand the character and individual consequences of the trial&#xD;
&#xD;
          -  Nasopharyngeal Carcinomas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof. Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>mechthild.krause@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Troost, Prof.Dr.Dr.</last_name>
    <phone>+49 351 458 7433</phone>
    <email>esther.troost@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Radiation Oncology, Vienna General Hospital (AKH)</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Faculty, Albert-Ludwigs-Universität Freiburg, Department of Radiation Oncology</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Grosu Anca, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology Heidelberg University Medical School</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jürgen Debus, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jürgen Debus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mechthild Krause</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Mechthild Krause, Prof. Dr.</last_name>
      <phone>+493512238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité University Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Volker Budach, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Stuschke, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian-Universität, Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Claus Belka, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facoltà di Medicina e Chirurgia - Università Cattolica S.C. Istituto di Radiologia, Radioterapia 1</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karol-Marcinkowski Medical University of Poznan, Department of Radiation Oncology, Greater Poland Cancer Center, Department of Radiotherapy</name>
      <address>
        <city>Poznań</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Director of the Department of Radiotherapy and Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>radiochemotherapy</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

